Diane M Hargrove, Sudarkodi Alagarsamy, Glenn Croston, Régent Laporte, Steve Qi, Karthik Srinivasan, Javier Sueiras-Diaz, Kazimierz Wiśniewski, Jennifer Hartwig, Mark Lu, Alexander P Posch, Halina Wiśniewska, Claudio D Schteingart, Pierre J-M Rivière, Violetta Dimitriadou
Glucagon-like peptide-2 (GLP-2) agonists have therapeutic potential in clinical indications in which the integrity or absorptive function of the intestinal mucosa is compromised, such as in short bowel syndrome (SBS). Native hGLP-2, a 33-amino acid peptide secreted from the small intestine, contributes to nutritional absorption but has a very short half-life because of enzymatic cleavage and renal clearance and thus is of limited therapeutic value. The GLP-2 analog teduglutide (Revestive/Gattex; Shire Inc.) has been approved for use in SBS since 2012 but has a once-daily injection regimen...
May 2020: Journal of Pharmacology and Experimental Therapeutics